U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07114432) titled 'RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma' on July 28.
Brief Summary: This is a single-arm, dose-escalation exploratory study evaluating the safety and efficacy of RN1201, a BCMA/CD19-targeted allogeneic CAR-T cell therapy, in patients with newly diagnosed cytogenetically high-risk multiple myeloma who are ineligible or unwilling to undergo autologous stem cell transplantation (ASCT). Patients will receive lymphodepletion followed by a single infusion of RN1201 across four dose levels. Primary endpoints include incidence and severity of treatment-emergent adverse events. Secondary endpoints assess re...